Ralf Reilmann

Best Publications

• Huntington disease: natural history, biomarkers and prospects for therapeutics

  Christopher A Ross;Elizabeth Hoppes Aylward;Edward J Wild;Douglas R Langbehn

  1113
  Citations

• Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

  Sarah J Tabrizi;Douglas R Langbehn;Blair R Leavitt;Raymund A C Roos

  1076
  Citations

• Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

  Sarah J Tabrizi;Rachael I Scahill;Gail N Owen;Alexandra Durr

  956
  Citations

• Technology in Parkinson's disease: Challenges and opportunities.

  Alberto J. Espay;Paolo Bonato;Fatta B. Nahab;Walter Maetzler

  688
  Citations

• Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

  Sarah J Tabrizi;Rachael I Scahill;Alexandra Durr;Raymund A C Roos

  686
  Citations

• Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

  Sarah J Tabrizi;Ralph Reilmann;Raymond A C Roos;Alexandra Durr

  602
  Citations

• Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

  Davina J Hensman Moss;Antonio F Pardiñas;Douglas Langbehn;Kitty Lo

  347
  Citations

• A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies

  Alberto J. Espay;Jeffrey M. Hausdorff;Jeffrey M. Hausdorff;Jeffrey M. Hausdorff;Álvaro Sánchez‐Ferro;Jochen Klucken

  290
  Citations

• Diagnostic Criteria for Huntington's Disease Based on Natural History

  Ralf Reilmann;CM Blair R. Leavitt Md;Christopher A. Ross

  246
  Citations

• International Guidelines for the treatment of Huntington’s Disease

  Anne Catherine Bachoud-Lévi;Joaquim Ferreira;Renaud Massart;Katia Youssov

  189
  Citations

• Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

  Justo Garcia de Yebenes;Bernhard Landwehrmeyer;Ferdinando Squitieri;Ralf Reilmann

  189
  Citations

• MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.

  Michael Flower;Vilija Lomeikaite;Marc Ciosi;Sarah Cumming

  169
  Citations

• Tapping linked to function and structure in premanifest and symptomatic Huntington disease

  N. Bechtel;R.I. Scahill;H.D. Rosas;T. Acharya

  169
  Citations

• Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease

  Eve M. Dumas;Simon J.A. van den Bogaard;Margot E. Ruber;Ralf Reilmann

  163
  Citations

• Creatine supplementation lowers brain glutamate levels in Huntington's disease.

  Andreas Bender;Dorothee P. Auer;Thomas Merl;Ralf Reilmann

  155
  Citations

• Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study

  Stefan Klöppel;Sarah Gregory;Elisa Scheller;Lora Minkova

  152
  Citations

• Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy

  Rachael I. Scahill;Nicola Z. Hobbs;Miranda J. Say;Natalie Bechtel

  139
  Citations

• Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease

  A. Sturrock;C. Laule;J. Decolongon;R. Dar Santos

  132
  Citations

• Coordination of prehensile forces during precision grip in Huntington's disease

  Andrew M. Gordon;Lori Quinn;Ralf Reilmann;Karen Marder

  123
  Citations

• Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

  Ralf Reilmann;Ralf Reilmann;Andrew McGarry;Igor D Grachev;Juha-Matti Savola

  109
  Citations